Pharmasset (VRUS) Posts Mixed Q211 Results; Loss Narrower than Expected
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts VRUS Hot Sheet
Join SI Premium – FREE
Pharmasset, Inc. (Nasdaq: VRUS) reported Q2 loss of $0.55, $0.10 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $247 thousand versus the consensus estimate of $440 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Rogers Communications (RCI) Tops Q3 EPS by 42c
- GrafTech International Ltd. (EAF) Misses Q3 EPS by 39c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
